Full Text View
Tabular View
No Study Results Posted
Related Studies
Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT
This study has been completed.
First Received: December 19, 2006   No Changes Posted
Sponsored by: Singapore General Hospital
Information provided by: Singapore General Hospital
ClinicalTrials.gov Identifier: NCT00413712
  Purpose

The purpose of this study is to determine the efficacy and effectiveness of calcium channel blockers and adenosine in the treatment of Supraventricular Tachycardia.


Condition Intervention Phase
Supraventricular Tachycardia
 Drug: Calcium Channel Blocker & Adenosine
 Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title: Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.

Resource links provided by NLM:

Genetics Home Reference related topics: Brugada syndrome short QT syndrome
MedlinePlus related topics: Calcium
Drug Information available for: Adenosine Calcium gluconate
U.S. FDA Resources

Further study details as provided by Singapore General Hospital:

Primary Outcome Measures:
  • Conversion to the sinus rhythm.

Secondary Outcome Measures:
  • Recurrence of SVT
  • Stability of vital signs

Estimated Enrollment: 206
Study Start Date: January 1997
Estimated Study Completion Date: March 2001
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • More than 10 years old
  • Electrocardiographic diagnosis of SVT
  • SVT not converted by the vagal manoeuvres

Exclusion Criteria:

  • Signs of impaired cerebral perfusion
  • Signs of pulmonary oedema
  • Subsequent diagnosis of other types of arrythmias rather than SVT
  • pregnancy by history
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00413712

Locations
Singapore
Singapore General Hospital
Singapore, Singapore, 62223322
Sponsors and Collaborators
Singapore General Hospital
Investigators
Principal Investigator: Lim S Han, MBBS,FRCS Department of Emergency Medicine, Singapore General Hospital
  More Information

Publications:
Lim SH, Anantharaman V, Teo WS. Slow-infusion of calcium channel blockers in the emergency management of supraventricular tachycardia. Resuscitation. 2002 Feb;52(2):167-74.
Brady WJ Jr, DeBehnke DJ, Wickman LL, Lindbeck G. Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med. 1996 Jun;3(6):574-85.
Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med. 1995 May;25(5):649-55.
Sethi KK, Singh B, Kalra GS, Arora R, Khalilullah M. Comparative clinical and electrophysiologic effects of adenosine and verapamil on termination of paroxysmal supraventricular tachycardia. Indian Heart J. 1994 May-Jun;46(3):141-4.
Viskin S, Belhassen B. Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies. Am Heart J. 1990 Jul;120(1):180-8. Review.
Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med. 1991 Dec 5;325(23):1621-9. Review. No abstract available.
Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991 Jul;20(7):717-21.
DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990 Jul 15;113(2):104-10. Erratum in: Ann Intern Med 1990 Dec 15;113(12):996.
Viskin S, Belhassen B. Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies. Am Heart J. 1990 Jul;120(1):180-8. Review.
Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis. 1989 Jul-Aug;32(1):73-97. Review. No abstract available.
Garratt C, Linker N, Griffith M, Ward D, Camm AJ. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol. 1989 Dec 1;64(19):1310-6.
Belhassen B, Glick A, Laniado S. Comparative clinical and electrophysiologic effects of adenosine triphosphate and verapamil on paroxysmal reciprocating junctional tachycardia. Circulation. 1988 Apr;77(4):795-805.
Klein HO, Ninio R, Oren V, Lang R, Sareli P, DiSegni E, David D, Guerrero J, Kaplinsky E. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography. Circulation. 1983 Jan;67(1):101-10.
Betriu A, Chaitman BR, Bourassa MG, Brevers G, Scholl JM, Bruneau P, Gagne P, Chabot M. Beneficial effect of intravenous diltiazem in the acute management of paroxysmal supraventricular tachyarrhythmias. Circulation. 1983 Jan;67(1):88-94.
Mitchell LB, Schroeder JS, Mason JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol. 1982 Feb 18;49(3):629-35.
Singh BN, Hecht HS, Nademanee K, Chew CY. Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):103-32. Review. No abstract available.
Kawai C, Konishi T, Matsuyama E, Okazaki H. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation. 1981 May;63(5):1035-42.
Henderson AH, Lewis MJ. Basic mechanisms of 'calcium antagonists' (slow channel blockers). Scott Med J. 1981 Apr;26(2):156-60. Review. No abstract available.
Russell DC. Electrophysiology and antiarrhythmic effects of calcium antagonists. Scott Med J. 1981 Apr;26(2):161-4. Review. No abstract available.
Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med. 1980 Nov;93(5):682-9.
Seipel L, Breithardt G, Abendroth RR, Wiebringhaus E. [The electrophysiological effects of the Ca-antagonists gallopamil (D 600), dimeditiapramine (Ro 11-1781) and verapamil in man (author's transl)] Z Kardiol. 1980 Aug;69(8):551-5. German.
Singh BN, Roche AH. Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J. 1977 Nov;94(5):593-9.
Heng MK, Singh BN, Roche AH, Norris RM, Mercer CJ. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J. 1975 Oct;90(4):487-98.
Schamroth L, Krikler DM, Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J. 1972 Mar 11;1(5801):660-2. No abstract available.

Study ID Numbers: IRB18/1997
Study First Received: December 19, 2006
Last Updated: December 19, 2006
ClinicalTrials.gov Identifier: NCT00413712     History of Changes
Health Authority: Singapore: Health Sciences Authority

Keywords provided by Singapore General Hospital:
Supraventricular Tachycardia
Calcium Channel Blockers
Verapamil
Diltiazem
Adenosine

Study placed in the following topic categories:
Tachycardia, Supraventricular
Vasodilator Agents
Heart Diseases
Tachycardia
Calcium Channel Blockers
Cardiovascular Agents
Calcium, Dietary
Verapamil
 Diltiazem
Emergencies
Analgesics
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Adenosine
Arrhythmias, Cardiac

Additional relevant MeSH terms:
Tachycardia, Supraventricular
Vasodilator Agents
Disease Attributes
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Tachycardia
Physiological Effects of Drugs
Calcium Channel Blockers
Cardiovascular Agents
Pharmacologic Actions
Membrane Transport Modulators
 Pathologic Processes
Sensory System Agents
Therapeutic Uses
Emergencies
Cardiovascular Diseases
Anti-Arrhythmia Agents
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Adenosine
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on July 06, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services